複製鏈接
請複製以下鏈接發送給好友

周文

(中南大學基礎醫學院腫瘤研究所研究員)

鎖定
周文,女,中國國籍,湖南嶽陽人,現任中南大學基礎醫學院腫瘤研究所研究員、博士生導師。 [1] 
中文名
周文
出生地
湖南嶽陽
畢業院校
中南大學
學位/學歷
博士
職    業
教師
專業方向
病理學與病理生理學

周文人物經歷

2009年獲中南大學湘雅醫學院病理學與病理生理學腫瘤專業醫學博士。2011-2013年先後在美國猶他大學醫學院和美國艾奧瓦大學醫學院從事博士後研究。 [1] 

周文研究方向

腫瘤癌變原理、腫瘤耐藥機制及腫瘤幹細胞研究,主要以造血系統惡性腫瘤多發性骨髓瘤為研究對象:1.利用單細胞技術探討多發性骨髓瘤(Multiple Myeloma, MM)細胞起源及建立耐藥過程中的克隆演進模型;2.利用微生物組學、代謝組學結合MM臨牀標本、MM鼠模型探討多發性骨髓瘤MM發生、發展及耐藥的分子機制。 [1] 

周文主要成就

研究成果以通訊作者或第一作者發表在Cancer Cell、Leukemia、Microbiome和Cell Reports等國際腫瘤學、血液學和生物學一流期刊上,並多次獲得美國血液學年會(ASH)口頭髮言。主持及參與國家重點研發計劃、國家自然科學基金委重點項目和麪上項目等課題。擔任中國細胞生物學會青年委員、中國細胞生物學會腫瘤委員會委員和中國生理學會血液生理委員會青年委員等學術任職。 [1] 

周文代表性論文

1.Jiliang Xia*, Jingyu Zhang*,Xuan Wu,Wanqing Du ,Yinghong Zhu,Xing Liu,Zhenhao Liu,Bin Meng,Jiaojiao Guo,Qin Yang, Yihui Wang, Qinglin Wang,Xiangling Feng,Guoxiang Xie,Yi Shen,Yanjuan He, Juanjuan Xiang, Minghua Wu, Gang An, Lugui Qiu, Wei Jia, Wen Zhou# Blocking glycine utilization inhibits multiple myeloma progression by disrupting glutathione balance[J] Nat Commun 2022 Jul 11;13(1):4007. PMID: 35817773 (IF=17.8)
2. Feng X*, Guo J*, An G, Wu Y, Liu Z, Meng B, He N, Zhao X, Chen S, Zhu Y, Xia J, Li X, Yu Z, Li R, Ren G, Chen J, Wu M, He Y, Qiu L, Zhou J, Zhou W#. Genetic Aberrations and Interaction of NEK2 and TP53 Accelerate Aggressiveness of Multiple Myeloma[J]. Adv Sci (Weinh). 2022 Mar;9(9):e2104491 PMID: 35088582(IF=16.8)
3. Xingxing Jian*, Yinghong Zhu*, Jian Ouyang, Qian Lei, Jiliang Xia, Jingyu Zhang, Jiaojiao Guo, Jinuo Wang, Jinchao Lin, Mingming Su, Yongjun Guan, Guancheng Li, Minghua Wu, Lugui Qiu, Jian Li, Juanjuan Xiang, Lu Xie, Lugui Qiu,Wei Jia and Wen Zhou#. Alterations of gut microbiome accelerate multiple myeloma progression by increasing the relative abundances of nitrogen-recycling bacteria[J]. Microbiome, 2020, 8(1). PMCID: PMC7257554(IF=14.6)
4 Jiliang Xia*, Yanjuan He*, Bin Meng, Shilian Chen, Jingyu Zhang, Xuan Wu, Yinghong Zhu, Yi Shen, Xiangling Feng, Yongjun Guan, Chunmei Kuang, Jiaojiao Guo, Qian Lei, Yangbowen Wu, Gang An, Guancheng Li, Lugui Qiu, Fenghuang Zhan and Wen Zhou#. NEK2 induces autophagy‐mediated bortezomib resistance by stabilizing Beclin‐1 in multiple myeloma[J]. Mol Oncol. 2020;14(4): 763-778. PMCID: PMC7138399 (IF=6.574)
5. Yu Wang, Hongtao Wang, Jiaojiao Guo, Jie Gao, Mengge Wang, Meijuan Xia, Yuqi Wen, Pei Su, Ming Yang, Mingyao Liu, Lihong Shi, Tao Cheng, Wen Zhou# and Jiaxi Zhou#. LGR4, Not LGR5, Enhances hPSC Hematopoiesis by Facilitating Mesoderm Induction via TGF-Beta Signaling Activation[J]. Cell Reports, 2020, 31(5): 107600. PMID: 32375050 (IF=8.109)
6. Xuan Wu*, Jiliang Xia*, Jingyu Zhang, Yinghong Zhu, Yangbowen Wu, Jiaojiao Guo, Shilian Chen, Qian Lei, Bin Meng, Chunmei Kuang, Xiangling Feng, Yanjuan He, Yi Shen, Xin Li, Lugui Qiu, Guancheng Li# and Wen Zhou#. Phosphoglycerate Dehydrogenase Promotes Proliferation and Bortezomib Resistance Through Increasing Reduced Glutathione Synthesis in Multiple Myeloma[J]. British Journal of Haematology. 2020;16(503). PMID: 32037523(IF=5.518)
7. Meirong Zang*, Jiaojiao Guo*, Lanting Liu*, Fengyan Jin*, Xiangling Feng, Gang An , Xiaoqi Qin, Yangbowen Wu , Qian Lei, Bin Meng , Yinghong Zhu, Yongjun Guan , Shuhui Deng, Mu Hao , Yan Xu, Dehui Zou , Minghua Wu , Lugui Qiu# and Wen Zhou#. Cdc37 suppression induces plasma cell immaturation and bortezomib resistance in multiple myeloma via Xbp1s[J]. Oncogenesis. 2020;9(3):31. PMCID: PMC7058164 (IF=6.119)
8. Yu Qin*, Shuaishuai Zhang*, Shuhui Deng*, Gang An, Xiaoqi Qin, Fei Li,Yan Xu, Mu Hao, Yijun Yang , Wen Zhou# (co-correpondence), Hong Chang# , Lugui Qiu#. Epigenetic silencing 1 of miR-137 induces drug resistance and chromosomal instability by targeting AURKA in multiple myeloma[J].Leukemia. 2017;31(5):1123-1135. PMID: 27857131(IF 12.1)
9. Zhou W*, Yang Y*, Gu Z,Wang H, Xia J, Wu X, Zhan X, Levasseur D, Zhou Y, Janz S, Tricot G, Shi J#, ZhanF#. ALDH1 Activity identifies tumor initiating cells and links to chromosomal instability signatures in multiple myeloma[J]. Leukemia. 2014;28(5):1155-8. PMID:24365790(IF 12.1)
10. Zhou W*, Yang Y*, Xia J*, Wang H*, Salama ME,Xiong W, Xu H, Shetty S, Chen T, Zeng Z, Shi L, Zangari M, Miles R, Bearss D,Tricot G#, Zhan F#. NEK2 induces drug resistance mainly through activation ofefflux drug pumps and is associated with poor prognosis in myeloma and other cancers[J]. Cancer Cell. 2013;23(1):48-62. PMID:23328480 (Article featured by Nature reviews drug discovery, recommend toF1000 prime, reviewed by Nature Reviews cancer, Blood et al.)(IF 24.7) [2] 

周文學術活動

擔任多個雜誌(Frontiers oncology, Cancers等)的編輯和審稿人。 [2] 
受邀在第53屆、第54屆、第60屆和第61屆美國血液學年會等多個國際會議上作大會發言,顯著擴大了中國多發性骨髓瘤研究在國際上的影響。 [3] 
參考資料